ClinicalTrials.gg
RecruitingNCT07643558SUPPORTUpdated Jun 11, 2026

Effects of Dietary Supplementation With omega3-fatty Acids (Fish Oil) and Progressive Resistance Training on Skeletal Muscle Status in Gynaecological, Gastrointestinal and Urological Cancer Patients

An interventional study of Omega 3 FA (Fish Oil) and Training in Cancer Cachexia, Omega 3 and Resistance Training, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of skeletal muscle mass, physical performance, and quality of life. Muscle wasting negatively affects the tolerability and efficacy of oncological therapies and exacerbates distressing symptoms such as fatigue. Consequently, international guidelines recommend combined nutritional and exercise interventions as key components of supportive cancer care. However, due to treatment-related limitations, conventional exercise programs are often difficult to implement, highlighting the need for feasible, time-efficient, and individually adaptable training concepts suitable for daily life.

In addition, adequate protein-rich nutrition is essential and may be supported by targeted nutritional supplementation. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have demonstrated anti-inflammatory effects and beneficial influences on nutritional status, quality of life, and potentially skeletal muscle mass.

The aim of the present project is to investigate, in a randomized, placebo-controlled trial, whether the combination of progressive resistance training (twice-weekly TheraBand-based exercise) and omega-3 supplementation (daily intake of 2 g EPA and 1 g DHA administered as fish oil capsules) can improve muscle status, physical performance, and patient-relevant outcomes such as quality of life, appetite, and fatigue in cancer patients at high risk of developing cancer cachexia.

02

Conditions studied

  • Cancer Cachexia
  • Omega 3
  • Resistance Training
  • Cancer
  • Muscle Wasting
  • Systemic Inflammation

Keywords

  • Resistance training
  • Progressive resistance exercise
  • Exercise therapy
  • Supportive cancer care
  • Nutritional intervention
  • Protein-rich nutrition
  • Nutritional supplementation
  • Omega-3 fatty acids
  • Eicosapentaenoic acid (EPA)
  • Docosahexaenoic acid (DHA)
  • Fish oil supplementation
  • Physical performance
  • Quality of life
  • Fatigue
  • Appetite
  • Patient-reported outcomes
  • Randomized placebo-controlled trial
  • Cachexia risk
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 288 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with malignant tumors undergoing curative or palliative treatment, including breast, ovarian, esophageal, pancreatic, gastric, colon, rectal, and prostate cancer, across all UICC stages
  • Women and men aged 18 years or older
  • performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • Patients younger than 18 years
  • Bone or skeletal involvement associated with a high risk of fracture
  • Pregnant or breastfeeding women
  • Patients with psychiatric disorders that raise concerns regarding decision-making capacity or ability to provide
  • Participation in other exercise and/or nutritional intervention studies within the previous 3 months
  • Current use of fish oil supplements
  • Severe cardiovascular disease, class IV
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • Placebo comparator
    Placebo, no training

    Placebo (corn oli) and no training program

    Dietary Supplement: Corn Oil Placebo, 4 capsules/day for 12 weeks

  • Placebo comparator
    Placebo, training group

    Placebo (corn oli) and 2x weekly resistance training

    Behavioral: Training · Dietary Supplement: Corn Oil Placebo, 4 capsules/day for 12 weeks

  • Experimental
    Omega-3, no training

    Verum (Omega-3-capsules with fish oil) and no training program

    Dietary Supplement: Omega 3 FA (Fish Oil)

  • Experimental
    Omega-3, training group

    Verum (Omega-3-capsules with fish oil) and 2x weekly resistance training

    Dietary Supplement: Omega 3 FA (Fish Oil) · Behavioral: Training

Interventions

  • Dietary supplementFish OilsStudies of Fish OilsFish Oils pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    4x capsules containing 500 mg EPA and 250 mg DHA

  • BehavioralTraining

    2x weekly resistance training

  • Dietary supplementCorn Oil Placebo, 4 capsules/day for 12 weeks

    4x capsueles daily

06

What researchers measure

Primary outcomes

  1. Skeletal Muscle Status I

    Body composition: BIA (SMM in kg)

    Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  2. Skeletal Muscle Status II

    Muscle function: Tensiomyography (TMG) (Dm in mm, Tc in ms, Td in ms, Ts in ms, Tr in ms)

    Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  3. Skeletal Muscle Status III

    Maximal muscle strength: estimated one-repetition maximum (1-RM in kg)

    Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  4. Skeletal Muscle Status IV

    Handgrip strength: dynamometer (in kg)

    Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  5. Physical Performance I

    Functional exercise capacity: 6-minute walk test (distance in m)

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  6. Physical Performance II

    Daily physical activity: International Physical Activity Questionnaire (IPAQ)

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  7. Physical Performance III

    Accelerometry over 7 consecutive days (steps)

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  8. Nutritional Status I

    Malnutrition screening: Nutritional Risk Screening Score (NRS 2002) \[0 (no risk) - 7 (highest risk)\]

    Time frame: baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 6 months follow-up after study completion

  9. Nutritional Status II

    Dietary intake and nutrient analysis: 3 or 7-day dietary record for assessment of energy and protein intake (in g)

    Time frame: baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 6 months follow-up after study completion

  10. Nutritional Status III

    Dietary intake and nutrient analysis: 3 or 7-day dietary record and assessment of consumption of EPA- and DHA-rich foods, and omega-3/omega-6 fatty acid ratio (in g)

    Time frame: baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 6 months follow-up after study completion

Secondary outcomes

  1. Patient-Reported Outcomes I

    Appetite perception: VAS-scale (Visual Analog Scale 0 \[none\] - 10 \[excessive\])

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  2. Patient-Reported Outcomes II

    Quality of life: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  3. Patient-Reported Outcomes III

    Fatigue: The Functional Assessment of Chronic Illness Therapy (FACIT) - Scale \[0-52, higher scores indicate better quality of life and less severe fatigue\]

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  4. Patient-Reported Outcomes III

    Symptom burden and treatment-related side effects: Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  5. Patient-Reported Outcomes IV

    Edmonton Symptom Assessment Scale (ESAS) \[0 (none) - 10 (worst possible)\]

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

  6. Omega-3-Index

    Laboratory Endpoints: Omega-3 Fatty Acid Status as Blood-Based Biomarkers

    Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion

07

Study locations

1 of 1 sites recruiting
  • Hector-Center for Nutrition, Exercise and Sports
    Erlangen, Bavaria 91056, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2028, 33 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 33 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jun 11, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2029
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07643558
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
Jan 1, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
Jun 11, 2026

Study contacts

Yurdagül Zopf, Prof. Dr. med.
study chair · Universitätsklinikum Erlangen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fish Oils

Start the discussion